SCHEMBL4816072

SCHEMBL4816072

CNC(=O)c1ccc(Cc2cn(C)c3cc(C#N)ccc23)c(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 5/20 0.44
HDAC8 Q9BY41 4/20 0.44
HDAC1 Q13547 4/20 0.44
HDAC3 O15379 3/20 0.44
HDAC2 Q92769 2/20 0.44
PTGER4 P35408 6/20 0.43
ALDH1A1 P00352 1/20 0.41
DUSP3 P51452 1/20 0.41
PLA2G4A P47712 1/20 0.38
LTB4R Q15722 1/20 0.38
CDK1 P06493 1/20 0.37
EDNRA P25101 1/20 0.35
IMPDH2 P12268 1/20 0.35
PGR P06401 1/20 0.34
BRD4 O60885 1/20 0.34
BRD2 P25440 1/20 0.34
BRD3 Q15059 1/20 0.34
BRDT Q58F21 1/20 0.34
SIRT1 Q96EB6 1/20 0.34
CPT2 P23786 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4812954 0.84 HDAC3 (0.39) HDAC6HDAC8HDAC1HDAC3HDAC2
SCHEMBL4813751 0.77 PLA2G4A (0.46) PLA2G4ALTB4RPGR
SCHEMBL4809830 0.73 PLA2G4A (0.37) HDAC6HDAC8HDAC1HDAC3HDAC2
SCHEMBL17680488 0.73 ALDH1A1 (0.46) HDAC6HDAC8HDAC1HDAC3HDAC2
SCHEMBL29282169 0.72 GPR84 (0.48) HDAC6HDAC8HDAC1HDAC3HDAC2
SCHEMBL20604909 0.70 PGR (0.42) HDAC6HDAC8HDAC1HDAC3HDAC2
SCHEMBL20787536 0.66 HDAC8 (0.47) HDAC6HDAC8HDAC2
SCHEMBL19538916 0.66 ALDH1A1 (0.40) HDAC6HDAC8HDAC1HDAC3HDAC2
SCHEMBL4808301 0.65 PGR (0.39) PLA2G4ALTB4RPGR
SCHEMBL1417979 0.65 HDAC2 (0.57) HDAC6HDAC8HDAC2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7417063-B2 Bicyclic heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-26 US disclosed
EP-1740538-A4 BICYCLIC HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2007-12-19 EP disclosed
EP-1740538-A2 BICYCLIC HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-01-10 EP disclosed
WO-2005099709-A2 BICYCLIC HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-27 WO disclosed
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent BRISTOL-MYERS SQUIBB COMPANY 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent F12, F11, F2 HDAC6 3538/4885HDAC8 868/4885HDAC1 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.